<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549363</url>
  </required_header>
  <id_info>
    <org_study_id>214098</org_study_id>
    <nct_id>NCT04549363</nct_id>
  </id_info>
  <brief_title>Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin</brief_title>
  <official_title>Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin (GSK2857916)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be available to any participant who has received or is currently receiving&#xD;
      belantamab mafodotin treatment through either a clinical trial, an access program, or a&#xD;
      physician prescription. Participants do not need to be on active treatment. The purpose of&#xD;
      this study is to gain a more complete understanding of the pathophysiology of the corneal&#xD;
      events seen in some participants with relapsed/refractory multiple myeloma (RRMM) treated&#xD;
      with belantamab mafodotin. A superficial corneal epithelial tissue specimen will be obtained&#xD;
      by performing impression cytology (IC) or superficial keratectomy (SK) procedure in&#xD;
      participants treated with belantamab mafodotin. The procedure will only be performed in one&#xD;
      eye, most affected by the corneal epithelial changes. This specimen will undergo pathologic&#xD;
      examination and composition analysis. Study duration will be approximately 4 months.&#xD;
      Approximately 25 participants will be enrolled in the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Anticipated">February 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 16, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with abnormality in composition of corneal epithelium after administration of belantamab mafodotin</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Corneal tissue samples will be collected to evaluate the composition of microcyst-like epithelium observed in participants treated with belantamab mafodotin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormality in pathologic characteristics after administration of belantamab mafodotin</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Corneal tissue samples will be collected to evaluate pathologic characteristics observed in participants treated with belantamab mafodotin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with non-serious adverse events (non-SAEs) and serious adverse events (SAEs) associated with IC or SK procedure</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Non-SAEs and SAEs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal best corrected visual acuity (BCVA) scores</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Number of participants with abnormal BCVA scores will be evaluated. The BCVA score is the number of letters read correctly by the participant. A decrease in the BCVA score indicates a worsening of vision while higher scores indicates improvement of visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal corneal symptoms</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Number of participants with abnormal corneal symptoms will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal corneal epithelial lesions</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Imaging of the corneal epithelial lesions will be done from slit-lamp examination and/or confocal microscopy, for evaluation of corneal epithelial lesions. Number of participants with abnormal corneal epithelial lesions will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Participants undergoing IC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IC will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination and who do not agree to undergo SK.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants undergoing SK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SK will be performed on some participants who received or are receiving treatment with belantamab mafodotin for RRMM and have objective evidence of keratopathy with corneal deposits on slit-lamp and/or confocal microscopy examination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belantamab mafodotin</intervention_name>
    <description>Belantamab mafodotin is a first-in-class immunoconjugate that targets B cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells.</description>
    <arm_group_label>Participants undergoing IC</arm_group_label>
    <arm_group_label>Participants undergoing SK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged 18 years or older (at the time consent is obtained).&#xD;
&#xD;
          -  Capable of providing signed written informed consent, which includes compliance with&#xD;
             the requirements and restrictions listed on the consent form.&#xD;
&#xD;
          -  Participants with RRMM who have received or are currently receiving treatment with&#xD;
             belantamab mafodotin and diagnosed with microcyst-like epithelial changes (MECs) on&#xD;
             slit-lamp examination or confocal microscopy, with or without symptoms, in at least&#xD;
             one eye.&#xD;
&#xD;
             a) If participants only had superficial punctate keratopathy with no evidence of MEC's&#xD;
             they are not eligible.&#xD;
&#xD;
          -  If undergoing SK procedure, treating provider has determined there is no excessive&#xD;
             risk to the participant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious and or/unstable medical or psychiatric disorder, or other conditions that&#xD;
             could interfere with the participant's safety.&#xD;
&#xD;
          -  Any excess risk of delayed wound healing (For example, diabetes mellitus).&#xD;
&#xD;
          -  Do not meet criteria specified by the study or program through which they would&#xD;
             receive belantamab mafodotin.&#xD;
&#xD;
          -  Any participant taking concurrent medication that may affect the cornea (that is.&#xD;
             amiodarone, some chloroquines).&#xD;
&#xD;
          -  Any participant with decreased corneal sensation.&#xD;
&#xD;
          -  Eye infections, including infectious keratopathy, stye, blepharitis, and&#xD;
             conjunctivitis.&#xD;
&#xD;
          -  An active uveitis including anterior, posterior, or panuveitis in either eye.&#xD;
&#xD;
          -  Permanent legal blindness in the fellow (non-study) eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sandy W Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Praneetha Thulasi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anjulie K Quick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wuqaas Mirza Munir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Malin Hultcrantz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hussam Banna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Belantamab mafodotin</keyword>
  <keyword>Impression cytology</keyword>
  <keyword>Superficial keratectomy</keyword>
  <keyword>Relapsed/Refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

